Clinical utilization of olaparib, a PARP inhibitor, in <em>BRCA1</em>-mutant metastatic acral melanoma

Ruixin Jiang; Xianbin Liang; Ye Tao; Ronghui Xia; Ming Lei; Bin Jiang; Robert L. Judson-Torres; Yanjie Zhang; Weizhen Zhang; Hanlin Zeng

doi:10.1016/j.gendis.2022.11.014

您当前的位置：

首页 >

文章列表页 >

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma

Short communication | 更新时间：2023-08-29

- Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
- Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
- Genes & Diseases 2023年10卷第5期
- 作者机构：
  
  1. Department of Dermatology, University of Utah,UT,Salt Lake City,USA,84132
  2. Department of Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China,201900
  3. Shanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China,200125
  4. Department of Oral & Maxillofacial - Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China,200125
  5. Huntsman Cancer Institute,UT,Salt Lake City,USA,84112
  6. Department of Oncology, The Third People's Hospital of Zhengzhou
  7. ,Henan,Zhengzhou,China,450000
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.11.014
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-9-1，
扫描看全文
Ruixin Jiang, Xianbin Liang, Ye Tao, 等. Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma[J]. Genes & Diseases, 2023,10(5).

Ruixin Jiang, Xianbin Liang, Ye Tao, et al. Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma[J]. Genes & Diseases, 2023,10(5).
Ruixin Jiang, Xianbin Liang, Ye Tao, 等. Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma[J]. Genes & Diseases, 2023,10(5). DOI： 10.1016/j.gendis.2022.11.014.

Ruixin Jiang, Xianbin Liang, Ye Tao, et al. Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma[J]. Genes & Diseases, 2023,10(5). DOI： 10.1016/j.gendis.2022.11.014.

摘要

Abstract

关键词

Keywords

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma

DOI：10.1016/j.gendis.2022.11.014

摘要

Abstract

关键词

Keywords

references